JP2017527533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527533A5 JP2017527533A5 JP2016575798A JP2016575798A JP2017527533A5 JP 2017527533 A5 JP2017527533 A5 JP 2017527533A5 JP 2016575798 A JP2016575798 A JP 2016575798A JP 2016575798 A JP2016575798 A JP 2016575798A JP 2017527533 A5 JP2017527533 A5 JP 2017527533A5
- Authority
- JP
- Japan
- Prior art keywords
- dkk2
- cancer
- antibody
- group
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 69
- 101710099523 Dickkopf-related protein 2 Proteins 0.000 claims description 48
- 206010028980 Neoplasm Diseases 0.000 claims description 46
- 201000011510 cancer Diseases 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 239000012472 biological sample Substances 0.000 claims description 19
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 18
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 18
- 201000002528 pancreatic cancer Diseases 0.000 claims description 18
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 18
- 230000003472 neutralizing effect Effects 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 230000000779 depleting effect Effects 0.000 claims description 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 10
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 201000002313 intestinal cancer Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 201000004101 esophageal cancer Diseases 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims description 6
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 230000004071 biological effect Effects 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 239000002955 immunomodulating agent Substances 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 239000000816 peptidomimetic Substances 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 108091023037 Aptamer Proteins 0.000 claims description 4
- 102000053642 Catalytic RNA Human genes 0.000 claims description 4
- 108090000994 Catalytic RNA Proteins 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- -1 antisense molecules Proteins 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 108091092562 ribozyme Proteins 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 101150108150 DKK2 gene Proteins 0.000 claims description 2
- 101100223943 Homo sapiens DKK2 gene Proteins 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims description 2
- 229940022399 cancer vaccine Drugs 0.000 claims description 2
- 238000009566 cancer vaccine Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 229940032219 immunotherapy vaccine Drugs 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 208000023589 ischemic disease Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000005747 tumor angiogenesis Effects 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 19
- 239000000463 material Substances 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 230000035772 mutation Effects 0.000 description 3
- 208000015768 polyposis Diseases 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020684P | 2014-07-03 | 2014-07-03 | |
| US62/020,684 | 2014-07-03 | ||
| PCT/US2015/038581 WO2016004055A1 (en) | 2014-07-03 | 2015-06-30 | Dickkopf2 (Dkk2) Inhibition Suppresses Tumor Formation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020183427A Division JP2021038232A (ja) | 2014-07-03 | 2020-11-02 | 腫瘍形成を抑制するディコップ２（Ｄｉｃｋｋｏｐｆ２）（Ｄｋｋ２）阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527533A JP2017527533A (ja) | 2017-09-21 |
| JP2017527533A5 true JP2017527533A5 (enExample) | 2018-08-02 |
| JP6789124B2 JP6789124B2 (ja) | 2020-11-25 |
Family
ID=55019920
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575798A Active JP6789124B2 (ja) | 2014-07-03 | 2015-06-30 | 腫瘍形成を抑制するディコップ２（Ｄｉｃｋｋｏｐｆ２）（Ｄｋｋ２）阻害 |
| JP2020183427A Withdrawn JP2021038232A (ja) | 2014-07-03 | 2020-11-02 | 腫瘍形成を抑制するディコップ２（Ｄｉｃｋｋｏｐｆ２）（Ｄｋｋ２）阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020183427A Withdrawn JP2021038232A (ja) | 2014-07-03 | 2020-11-02 | 腫瘍形成を抑制するディコップ２（Ｄｉｃｋｋｏｐｆ２）（Ｄｋｋ２）阻害 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10398765B2 (enExample) |
| EP (2) | EP3164194B1 (enExample) |
| JP (2) | JP6789124B2 (enExample) |
| CN (2) | CN106659912B (enExample) |
| CA (1) | CA2953149A1 (enExample) |
| ES (1) | ES2903029T3 (enExample) |
| WO (1) | WO2016004055A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017074774A1 (en) * | 2015-10-28 | 2017-05-04 | Yale University | Humanized anti-dkk2 antibody and uses thereof |
| WO2018174984A1 (en) * | 2017-03-24 | 2018-09-27 | Yale University | Low-density lipoprotein receptor related protein 5 inhibition suppresses tumor formation |
| JP2022526166A (ja) * | 2019-03-29 | 2022-05-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗癌併用療法 |
| CN112180094A (zh) * | 2019-07-04 | 2021-01-05 | 上海东慈生物科技有限公司 | Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用 |
| EP3996745A4 (en) * | 2019-07-10 | 2023-04-12 | Yale University | COMPOSITIONS AND METHODS OF USE OF HUMANIZED ANTI-DKK2 ANTIBODY |
| US20230340089A1 (en) * | 2020-05-14 | 2023-10-26 | City Of Hope | Smc1a antibodies and uses thereof |
| GB202008860D0 (en) * | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| CN112592402B (zh) * | 2020-12-02 | 2022-04-26 | 杭州奕安济世生物药业有限公司 | 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途 |
| WO2022271552A1 (en) * | 2021-06-21 | 2022-12-29 | Empirico Inc. | Treatment of dkk2 related diseases and disorders |
| WO2024137663A2 (en) * | 2022-12-20 | 2024-06-27 | Empirico Inc. | Treatment of dkk2 related diseases and disorders |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| CA2093664C (en) | 1990-10-12 | 2003-07-29 | Fritz Eckstein | Modified ribozymes |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6133232A (en) | 1996-06-20 | 2000-10-17 | The Regents Of The University Of California | Endoderm, cardiac and neural inducing factors |
| US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| AU5233599A (en) * | 1998-07-31 | 2000-02-21 | Eli Lilly And Company | Ddkh-3 nucleic acids, polypeptides, vectors, host cells, methods and uses thereof |
| US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| AU2002256371B2 (en) | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US7491530B2 (en) | 2001-12-18 | 2009-02-17 | Whitehead Institute For Biomedical Research | Fusion partner cells and uses thereof |
| US20060204496A1 (en) | 2003-11-28 | 2006-09-14 | Tetsuo Kojima | Agonist antibody against heteroreceptor |
| US8343922B2 (en) * | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| WO2007122815A1 (ja) * | 2006-04-14 | 2007-11-01 | Ono Pharmaceutical Co., Ltd. | Ｂｉｒ１に対する二価抗体 |
| WO2008045962A2 (en) * | 2006-10-10 | 2008-04-17 | Mayo Foundation For Medical Education And Research | Methods and materials related to anti-a (beta) antibodies |
| NZ589436A (en) | 2008-06-03 | 2012-12-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| RU2010153580A (ru) * | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двумя вариабельными доменами и их применение |
| IL318221A (en) * | 2012-05-15 | 2025-03-01 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting PD–1/PD–L1 signaling |
-
2015
- 2015-06-30 CN CN201580036541.2A patent/CN106659912B/zh active Active
- 2015-06-30 ES ES15816061T patent/ES2903029T3/es active Active
- 2015-06-30 CN CN202111337246.4A patent/CN114306605A/zh active Pending
- 2015-06-30 EP EP15816061.4A patent/EP3164194B1/en active Active
- 2015-06-30 JP JP2016575798A patent/JP6789124B2/ja active Active
- 2015-06-30 EP EP21208628.4A patent/EP3978524A1/en active Pending
- 2015-06-30 US US15/322,595 patent/US10398765B2/en active Active
- 2015-06-30 CA CA2953149A patent/CA2953149A1/en not_active Abandoned
- 2015-06-30 WO PCT/US2015/038581 patent/WO2016004055A1/en not_active Ceased
-
2019
- 2019-08-01 US US16/529,174 patent/US11497799B2/en active Active
-
2020
- 2020-11-02 JP JP2020183427A patent/JP2021038232A/ja not_active Withdrawn
-
2022
- 2022-10-06 US US17/938,549 patent/US20230190897A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527533A5 (enExample) | ||
| Mantovani et al. | Tumour-associated macrophages as treatment targets in oncology | |
| US11584788B2 (en) | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms | |
| Affara et al. | B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas | |
| KR102571924B1 (ko) | c-MAF 상태에 기초한 유방암의 치료 | |
| ES2995194T3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| Santosh et al. | Grade-Specific Expression of Insulin-like Growth Factor–Binding Proteins-2,-3, and-5 in Astrocytomas: IGFBP-3 Emerges as a Strong Predictor of Survival in Patients with Newly Diagnosed Glioblastoma | |
| US20220323478A1 (en) | Agents for the treatment of diseases associated with undesired cell proliferation | |
| CN109069601B (zh) | 使用与检查点抑制剂组合的溶瘤病毒的癌症疗法 | |
| US20200108066A1 (en) | Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors | |
| US11137404B2 (en) | Method for assessing the response to PD-1/PDL-1 targeting drugs | |
| JP2019503984A5 (enExample) | ||
| KR20160061424A (ko) | 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법 | |
| CA2963091A1 (en) | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response | |
| RU2018119317A (ru) | Гуманизированное антитело к dkk2 и его применение | |
| Yu et al. | Tumor-associated macrophages affect the treatment of lung cancer | |
| Liu et al. | LncRNA IL21-AS1 facilitates tumour progression by enhancing CD24-induced phagocytosis inhibition and tumorigenesis in ovarian cancer | |
| Miyar et al. | Predictive and prognostic value of TLR9 and NFKBIA gene expression as potential biomarkers for human glioma diagnosis | |
| US20220370608A1 (en) | Inhibitors of chi3l1 and their uses | |
| US20180148793A1 (en) | Biomarkers and uses thereof for selecting pancreas cancer intervention | |
| WO2012074842A2 (en) | Compositions and methods for treating neoplasia | |
| WO2011107939A1 (en) | Methods of predicting efficacy of an anti-vegfa treatment for solid tumors | |
| Zhang et al. | Zinc finger RNA-binding protein promotes non-small-cell carcinoma growth and tumor metastasis by targeting the Notch signaling pathway | |
| CN116322753A (zh) | 用于胰腺癌评价和治疗的方法和组合物 | |
| JP2012525121A5 (enExample) |